Literature DB >> 21114644

Glomerular filtration rate following pediatric liver transplantation--the SPLIT experience.

K Campbell1, V Ng, S Martin, J Magee, J Goebel, R Anand, K Martz, J Bucuvalas.   

Abstract

Impaired kidney function is a well-recognized complication following liver transplantation (LT). Studies of this complication in children have been limited by small numbers and insensitive outcome measures. Our aim was to define the prevalence of, and identify risk factors for, post-LT kidney dysfunction in a multicenter pediatric cohort using measured glomerular filtration rate (mGFR). We conducted a cross-sectional study of 397 patients enrolled in the Studies in Pediatric Liver Transplantation (SPLIT) registry, using mGFR < 90 mL/min/1.73 m(2) as the primary outcome measure. Median age at LT was 2.2 years. Primary diagnoses were biliary atresia (44.6%), fulminant liver failure (9.8%), metabolic liver disease (16.4%), chronic cholestatic liver disease (13.1%), cryptogenic cirrhosis (4.3%) and other (11.8%). At a mean of 5.2 years post-LT, 17.6% of patients had a mGFR < 90 mL/min/1.73 m(2) . In univariate analysis, factors associated with this outcome were transplant center, age at LT, primary diagnosis, calculated GFR (cGFR) at LT and 12 months post-LT, primary immunosuppression, early post-LT kidney complications, age at mGFR, height and weight Z-scores at 12 months post-LT. In multivariate analysis, independent variables associated with a mGFR <90 mL/min/1.73 m(2) were primary immunosuppression, age at LT, cGFR at LT and height Z-score at 12 months post-LT. ©2010 The Authors Journal compilation©2010 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114644     DOI: 10.1111/j.1600-6143.2010.03316.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

1.  Risk factors for end-stage kidney disease after pediatric liver transplantation.

Authors:  R L Ruebner; P P Reese; M R Denburg; E B Rand; P L Abt; S L Furth
Journal:  Am J Transplant       Date:  2012-09-20       Impact factor: 8.086

2.  Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience.

Authors:  Vicky L Ng; Estella M Alonso; John C Bucuvalas; Geoff Cohen; Christine A Limbers; James W Varni; George Mazariegos; John Magee; Susan V McDiarmid; Ravinder Anand
Journal:  J Pediatr       Date:  2011-12-20       Impact factor: 4.406

Review 3.  The SPLIT research agenda 2013.

Authors:  Estella M Alonso; Vicky L Ng; Ravinder Anand; Christopher D Anderson; Udeme D Ekong; Emily M Fredericks; Katryn N Furuya; Nitika A Gupta; Stacee M Lerret; Shikha Sundaram; Greg Tiao
Journal:  Pediatr Transplant       Date:  2013-05-30

4.  Reducing pediatric liver transplant complications: a potential roadmap for transplant quality improvement initiatives within North America.

Authors:  M J Englesbe; B Kelly; J Goss; A Fecteau; J Mitchell; W Andrews; G Krapohl; J C Magee; G Mazariegos; S Horslen; J Bucuvalas
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

Review 5.  Long term outcomes after pediatric liver transplantation.

Authors:  Nada A Yazigi
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-12-31

6.  Health status in young adults two decades after pediatric liver transplantation.

Authors:  S Mohammad; L Hormaza; K Neighbors; P Boone; M Tierney; R K Azzam; Z Butt; E M Alonso
Journal:  Am J Transplant       Date:  2012-05-08       Impact factor: 8.086

Review 7.  Kidney disease in children with heart or liver transplant.

Authors:  Amrit Kirpalani; Chia Wei Teoh; Vicky Lee Ng; Anne I Dipchand; Mina Matsuda-Abedini
Journal:  Pediatr Nephrol       Date:  2021-02-18       Impact factor: 3.714

Review 8.  Long-term outcomes of children after solid organ transplantation.

Authors:  Jon Jin Kim; Stephen D Marks
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.